KINIKSA A BE-,000273235 Logo
BMG5269C1010
A2JMVJ
KNSA

KINIKSA A BE-,000273235

Loading quotes...

Forecast

The analysts' average price target is €84.34 (-3.49%). The median is €89.33 (+2.22%).

Buy
  11
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Kiniksa significantly increases ARCALYST sales and advances IL-1 pipeline

    Kiniksa reported Q2 net sales of about $243 million for ARCALYST, an increase of $29 million versus the prior quarter and the strongest growth since market launch. The company says it is profitable and is targeting a positive annual cash‑flow trajectory. KPL-387 has entered the Phase III study of the PASTEURAL program with the goal of once‑monthly dosing and a possible launch in 2028–2029; KPL-1161 is being developed as a potential quarterly option. Kiniksa sees additional market potential in recurrent pericarditis and highlights a growing prescriber base and solid payer support. » More on de.investing.com


  • Kiniksa Pharmaceuticals reaches record high at $64.85

    Kiniksa Pharmaceuticals’ stock rose to a record high of $64.85 and is up 130.88% year-to-date. The company has a market capitalization of $4.96 billion and reported revenue growth of 57% in the past year. For Q1 2026, Kiniksa reported earnings per share of $0.27 (expectation $0.21) and revenue of $214.3 million (expectation $207.1 million). InvestingPro rates the stock close to its fair value but notes an overbought RSI. » More on de.investing.com


  • Kiniksa raises guidance after strong Q1 – ARCALYST revenue grows 56%

    Kiniksa reported ARCALYST revenue of US$214.3 million in Q1 2026 (up 56% year‑on‑year) and EPS of $0.27, beating expectations. The company raised its full-year guidance for net product sales of ARCALYST to US$930–945 million (previously US$900–920 million). Net income, operating margin and cash increased substantially; management highlighted market expansion, direct‑to‑consumer marketing and ongoing clinical programs KPL‑387 and KPL‑1161. The stock rose sharply after the results and is approaching its 52‑week high. » More on de.investing.com


  • Kiniksa reports strong Q1 2026 thanks to ARCALYST and raises full-year guidance

    Kiniksa recorded significant revenue growth from ARCALYST in Q1 2026 to $214.3 million (+56% y/y) and raised its full-year guidance to $930–945 million. Net income and operating income increased markedly; earnings per share were $0.27, beating expectations. The company broadened its prescriber base and now addresses patients with a first relapse; commercial momentum and pipeline candidates KPL-387 and KPL-1161 are expected to support further growth. Liquidity and the balance sheet improved, while higher revenue-linked collaboration costs and rising R&D spending temper the margin profile. » More on de.investing.com


  • Kiniksa Pharmaceuticals reaches profitability after strong Arcalyst growth, stock falls premarket

    Kiniksa Pharmaceuticals reported Q4 2025 revenue of $202.1 million (+65% versus Q4 2024) and a net profit of $14.2 million after a net loss in the year‑ago quarter. For full-year 2025 the company posted revenue of $677.6 million (+62%) and a net income of $59 million. The strong performance was driven mainly by Arcalyst; Kiniksa has $414.1 million in cash and plans to expand the IL‑1 franchise and advance KPL‑387. Despite the results, the stock fell 6.44% premarket to $44.34. » More on de.investing.com

Financials

In the last quarter, KINIKSA A BE-,000273235 had revenue of €252.47M and net profit of €41.8M
(EUR) September 2026
YoY
Revenue 252.47M 63.82%
Gross profit 134.53M 62.32%
Net profit 41.8M 166.08%
EBITDA 52.57M 124.01%

Fundamentals

Metric Value
Market capitalization
€6.86B
Number of shares
78.57M
52-week high/low
€90.06 - €33.57
Dividends No
Beta
0.08
P/E ratio
67.36
PEG ratio
0.35
P/B ratio
10.61
P/S ratio
8.00

Company profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Name
KINIKSA A BE-,000273235
CEO
Sanj K. Patel
Headquarters London, gl
Bermuda
Website
Sector
Materials
Industry
Chemicals
IPO
05/25/2018
Employees 366

Ticker symbols

Exchange Symbol
NASDAQ
KNSA
🍪

Parqet  uses cookies. Learn more